Leptomycin Biosynthesis via Recombinant Gene Clusters
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of leptomycin B and its analogs is hindered by variability in quality due to structural similarities in natural sources, and existing methods lack a reliable source of pure drug and a less toxic form, limiting their development as anticancer or antiviral agents.
Innovation Solution
The use of recombinant nucleic acids encoding polyketide synthases and modification enzymes for the biosynthesis of leptomycin and its analogs in heterologous hosts, allowing for the production of pure forms and potentially less toxic variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural sources are used for leptomycin production, then the drug can be obtained, but the quality varies due to structural similarities in natural sources
Solution Approach 1:
The patent uses recombinant DNA technology to copy the leptomycin biosynthesis gene cluster from the natural producer Streptomyces sp. ATCC 39366 into heterologous host cells. This allows replication of the exact biosynthetic pathway without relying on the natural source, thereby eliminating quality variability while maintaining production reliability.
Solution Approach 2:
The patent introduces an intermediary approach by using heterologous host cells (such as E. coli or other bacteria) that do not naturally produce leptomycin. These host cells serve as intermediaries to express the imported biosynthetic gene cluster, providing a controlled and reliable production system independent of the natural source's variability.
2Manufacturing precision
If existing production methods are used, then leptomycin can be produced, but the source is not reliable for pure drug production
Solution Approach 1:
The patent extracts and isolates the leptomycin biosynthesis gene cluster from the natural source Streptomyces sp. ATCC 39366, separating it from the complex natural production system. This extracted gene cluster can then be independently expressed in heterologous hosts, ensuring pure drug production without contamination from other natural source components.
Solution Approach 2:
By copying the complete biosynthetic gene cluster into heterologous hosts, the patent creates a reliable production system that can consistently deliver pure leptomycin. The heterologous hosts provide a controlled environment that ensures manufacturing precision while the copied genes maintain the original biosynthetic fidelity.
3Adaptability or versatility
If natural leptomycin is used, then the drug is available, but toxic forms limit therapeutic development
Solution Approach 1:
The patent enables parameter changes in the leptomycin molecule by using heterologous expression systems that can produce analogs and derivatives with modified structures. These parameter changes include altered molecular weight, charge distribution, or functional groups that reduce toxicity while maintaining therapeutic activity, thereby expanding therapeutic potential.
Solution Approach 2:
The patent applies local quality modification by selectively altering specific regions of the leptomycin molecule through enzymatic or chemical modification in the heterologous system. This allows creation of variants with improved pharmacological properties and reduced toxicity at specific molecular locations while preserving the core therapeutic function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of leptomycin and its analogs in large quantities with reduced impurities, enhancing their therapeutic potential as anticancer and antiviral agents by providing a reliable and less toxic form.
Implementation Method 1
Type I PKSs are large multifunctional protein complexes, the protein components of which are encoded by multiple open reading frames (ORF) of PKS gene clusters. Each ORF of a Type I PKS gene cluster can encode one, two, or more modules of ketosynthase activity. Each module activates and incorporates a two-carbon (ketide) unit into the polyketide backbone.
Implementation Method 2
Polyketide synthesis may also involve the activity of nonribosomal peptide synthetases (NRPSs) to catalyze incorporation of an amino acid-derived building block into the polyketide
Implementation Method 3
The modification enzymes modify the polyketide by oxidation or reduction, addition of carbohydrate groups or methyl groups, or other modifications.
Implementation Method 4
The modification enzymes modify the polyketide by oxidation or reduction, addition of carbohydrate groups or methyl groups, or other modifications.
Data Source
AI summary
Polypeptides and domains of leptomycin polyketide synthase and the nucleic acids encoding them are provided. Methods to prepare leptomycin, leptomycin analogs, and leptomycin derivatives are described, as are methods to prepare other polyketides using the nucleic acids encoding leptomycin polyketide synthase domains or modifying enzymes.